Novo Nordisk shares tumbled in pre-market trading on Monday after its experimental obesity drug CagriSema failed to match the weight-loss efficacy of Eli Lilly’s...
Eli Lilly & Co. and Novo Nordisk A/S secured deals with the Trump administration to slash prices for their blockbuster weight-loss drugs like Zepbound...